bioihbjkbjnl/mcl2 huggingface dataset:
The Association of Clinical Symptom Clusters With Underlying Mechanisms in Functional Gastrointestinal Disorders
Condition: Functional Gastrointestinal Disorders
MeSH terms: Gastrointestinal Diseases; Digestive System Diseases; Syndrome
Study type: Observational

Summary: 
      Functional gastrointestinal disorders (FGID) are amongst the most common causes of abdominal
      pain and dysfunction seen in clinical practice, affecting between 10 to 15% of most
      populations (1). FGID are defined by symptoms without demonstrable underlying organic
      pathology (2). Within the currently used Rome definitions of FGID, there is a broad range of
      gastrointestinal and multi-organ symptoms, indicating heterogeneous underlying
      pathophysiological mechanisms (3). There is evidence of central nervous system and motility
      dysfunction, dysbiosis, as well as immune activation in various subgroups of patients with
      FGID (2). Most mechanistic studies have been performed in small and heavily selected groups
      of patients. Consequently, the link between different symptomatic subgroups of patients and
      underlying mechanisms is unclear and unconfirmed in larger and representative patient
      cohorts. FGID patients with different underlying pathologies are likely to benefit from
      divergent specific treatments, even if they fall within the same Rome classification of FGID.

      Discrete clusters of clinical characteristics in a large cohort of patients with FGID will be
      sought using hypothesis-free cluster analysis and latent-class analysis models. Associations
      to underlying mechanisms will be examined using data from fermentable sugar breath, blood and
      stool tests. This will allow recommendations regarding improved mechanistic-based
      classifications of patients with FGID, with potential for more effective mechanistic-based
      treatments.

      The investigators will use coded clinical and medical history characteristics obtained by
      standardized questionnaires and laboratory and breath test results from all successive
      patients above the age of 18 years referred to the Gastroenterology Group Practice in the
      last 10 years for diagnosis and treatment of FGID for statistical analysis The data is stored
      in a database, without any personal identifiers. Explorative statistical analysis will be
      performed in approximately 5000 patients.
    


Intervention name(s): Observation
Intervention type(s): Other
Intervention description(s): observational
Observational model: Cohort
Time perspective: Retrospective
Sampling method: Non-Probability Sample
Study population: 
        Male and female patients classified as having FGID at time of referral, based on Rome III
        criteria, and age over 18 years
      
Keywords: Irritable Bowel Syndrome; Functional Dyspepsia
Efficacy of Potassium Nitrate Solution in Reducing Dentinal Hypersensitivity
Condition: Dentine Hypersensitivity
MeSH terms: Dentin Sensitivity; Hypersensitivity
Study type: Interventional
Phase: Phase 2

Summary: 
      An exploratory study investigating the direct application of potassium nitrate (KNO3)
      solutions of different concentrations in reducing dentine hypersensitivity.
    


Intervention name(s): 5% Potassium nitrate; 2.5% Potassium nitrate; Sterile water
Intervention type(s): Drug; Drug; Other
Intervention description(s): 5% potassium nitrate solution; 2.5% potassium nitrate solution; Sterile water
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: potassium nitrate; tooth sensitivity; dentin sensitivity
A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants.
Condition: Infections, Rotavirus
MeSH terms: Rotavirus Infections
Study type: Interventional
Phase: Phase 3

Summary: 
      The main objectives of this study are: 1) In a subset (N = 20 000), to determine vaccine
      efficacy against severe rotavirus (RV) gastroenteritis (GE) during the period starting from 2
      weeks after Dose 2 until one year of age. 2) In all subjects (N = 60 000), to determine the
      safety of GSK Biologicals' HRV vaccine with respect to definite intussusception (IS) within
      31 days (Day 0-Day 30) after each HRV vaccine dose.
    

Detailed description: 
      The study has two groups: Group HRV and Group Placebo. Two oral doses administered to healthy
      infants who are 6-13 weeks of age at the time of Dose 1, according to a 0, 1 to 2-month
      schedule. Routine EPI vaccinations are given at the discretion of the investigator and
      according to local National Plans of Immunisation schedule in each participating country. A
      minimum 2-week interval was to be observed between HRV vaccine and OPV doses. Of the total
      enrolled cohort of 60 000 subjects, 20 000 subjects were followed for efficacy and safety
      until one year of age while 40 000 subjects were followed for safety only until 30-90 days
      after the second HRV/placebo dose. A subset (N = approximately 13 000) of the 20 000 subjects
      are followed for efficacy and safety until 24 months of age. From the 20 000 subjects
      followed for efficacy and safety, a subset of 100 subjects per country (center specific,
      except Finland) provided two blood sample to evaluate immunogenicity.
    

Intervention name(s): Rotavirus
Intervention type(s): Biological
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Prevention
An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine
Condition: Chronic Hepatitis C Infection; Chronic Hepatitis C
MeSH terms: Infections; Communicable Diseases; Hepatitis A; Hepatitis C; Hepatitis C, Chronic; Hepatitis; Hepatitis, Chronic
Study type: Interventional
Phase: Phase 2

Summary: 
      The purpose of this study is to evaluate the safety and efficacy of ABT-450/ritonavir/ABT-267
      (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and
      ABT-333 (also known as dasabuvir) coadministered with ribavirin (RBV) in hepatitis C virus
      (HCV) genotype 1-infected adults taking methadone or buprenorphine ± naloxone.
    

Detailed description: 
      This study consisted of 2 periods: a 12-week treatment period and a 48-week post-treatment
      period (for all participants who received study drugs). All participants who received at
      least 1 dose of study drug were to be followed for 48 weeks post-treatment to monitor for
      safety, HCV RNA, the emergence and/or persistence of resistant viral variants, and assessment
      of patient-reported outcome (PRO) instruments.
    

Intervention name(s): ABT-450/r/ABT-267; ABT-333; Ribavirin (RBV)
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Tablet; ABT-450 coformulated with ritonavir and ABT-267; Tablet; Tablet
Other intervention name(s): ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir; dasabuvir
Intervention MeSH terms: Ribavirin
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: HCV Genotype 1; Hepatitis Genotype 1; Interferon Free; methadone; HCV; Buprenorphine; Hepatitis C; Viekira Pak; paritaprevir; Viekira; ombitasvir; dasabuvir
Bupropion as an Adjunct to the Nicotine Patch Plus CBT
Condition: Tobacco Use Disorder
MeSH terms: Tobacco Use Disorder
Study type: Interventional
Phase: Phase 4

Summary: 
      Existing and new pharmacotherapies along with prevention efforts are key to improving smoking
      cessation rates and reducing the premature morbidity and mortality associated with tobacco
      use. A number of individuals suffer from both nicotine dependence and depression. The purpose
      of this study is to determine the effectiveness of bupropion used in combination with the
      nicotine replacement patch and cognitive behavior therapy (CBT) in treating nicotine
      dependent individuals also diagnosed with depression.
    

Detailed description: 
      Smoking cessation treatment is highly cost effective and pharmacotherapy is universally
      recommended for treatment of nicotine dependence. However, the majority of smokers are unable
      to quit even with treatment. Existing and new pharmacotherapies along with prevention efforts
      are key to improving smoking cessation rates and reducing the premature morbidity and
      mortality associated with tobacco use. The purpose of this study is to examine the
      effectiveness of bupropion as an addition to a standard smoking cessation treatment of CBT
      and nicotine replacement. In addition, this study will determine if bupropion improves an
      individual's odds of quitting smoking, and whether this is achieved through its impact on
      negative mood states associated with depression.

      Participants in this double-blind study will be randomly assigned to receive either bupropion
      or placebo. CBT sessions and individual meetings with a study physician will last for 13
      weeks. Treatment with either bupropion or placebo will begin at the first CBT meeting and
      will continue for 13 weeks. Treatment with the nicotine replacement patch will begin at the
      second CBT meeting and will continue for 10 weeks. Participants will have monthly follow-up
      visits throughout the year following Week 13. During the follow-up period, participants will
      continue to take either bupropion or placebo but will no longer undergo CBT or nicotine
      replacement. If participants are unable to quit smoking, or become more depressed during the
      follow-up phase, they will be offered treatment with Zoloft, and will continue to be
      monitored for the duration of the follow-up year. If participants have been unsuccessful in
      using Zoloft, they will be offered another antidepressant at the judgement of the clinician.
    

Intervention name(s): Pharmacotherapies for Smoking Cessation
Intervention type(s): Drug
Intervention description(s): Bupropion-SR or Identical Placebo
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: nicotine dependence
Novel Equation for Estimating Intraperitoneal Pressure
Condition: Intraperitoneal Pressure; Peritoneal Dialysis; Equation
Study type: Observational

Summary: 
      Intraperitoneal Pressure is associated with the complications of increased intra-abdominal
      pressure in peritoneal dialysis patients. Due to the complicated operations, routine
      measurement of hydrostatic intraperitoneal pressure is not used routinely in adult peritoneal
      dialysis patients. There ars some limitions in equations from previous studies, such as the
      sample size was small , and the study population was limited. In the study, we aim to develop
      and validate an equation for estimating intraperitoneal pressure in peritoneal patients.
    


Observational model: Case-Only
Time perspective: Cross-Sectional
Sampling method: Non-Probability Sample
Study population: 
        All peritoneal dialysis patients meet the inclusion and exclusion criteria in a single
        center
Patients' Preferences for Traditional Medicine Doctor's Attire
Condition: Attire Preference
Study type: Observational

Summary: 
      Doctors' attire has known to impact patients' trust and confidence for better clinical
      practice. However, few survey research regarding this topic has been conducted in traditional
      asian medicine field. The aim of our study is to determine whether traditional medicine
      doctor's attire impacts on patients' confidence and trust.

      Participants will be given randomly one set of photographs from the 2 kind of photographs,
      i.e., photographs of a male or female doctor, each set dressed in 4 different styles.

      After this, they will be asked to report their preferences for the 4 styles of dress
      according to given questions and they will answer the degree of their feeling on the
      importance of Korean Medicine doctor's appearance.
    

Detailed description: 
      After seeing one set of photographs, participants will answer the questions below.

      Choose the most appropriate attire from the four dressing styles (a.formal wear
      b.conventional white coat c.white coat in traditional form d. casual wear) to the questions
      below (1-10).

        1. Which attire of Korean medicine doctor would you trust the most?

        2. Which attire of Korean medicine doctor would you be more likely to follow their advice?

        3. Which attire of Korean medicine doctor would you recommend to your acquaintance?

        4. Which attire of Korean medicine doctor would you be the most comfortable ?

        5. Which attire of Korean medicine doctor would you prefer to discuss an intimate social
           problem or a private issue?

        6. Which attire of Korean medicine doctor would you prefer for a minor medical problem(eg,
           a cold)?

        7. Which attire of Korean medicine doctor would you expect to be the most clean?

        8. Which attire of Korean medicine doctor would you expect to be the most hygienic?

        9. Which attire of Korean medicine doctor would you expect not to spread infectious germs
           to others?

       10. Which attire of Korean medicine doctor would you have the most confidence in their
           diagnosis and treatment when they perform clinical examination by touching you?

       11. How strongly do you feel about the importance of Korean medicine doctor's appearance?

             1. extremely important

             2. quite important

             3. important

             4. a little important

             5. not at all important
    

Observational model: Case-Only
Time perspective: Cross-Sectional
Sampling method: Probability Sample
Study population: 
        People in the Outpatient Waiting Room
      
Keywords: People in the outpatient waiting room
Adult Follow-up of Preventive Study With Brief Smoking Intervention for Adolescents
Condition: Smoking
Study type: Interventional

Summary: 
      The purpose of this study was to see whether a brief intervention given in adolescence has an
      effect on smoking in adulthood. The investigators also wanted to clarify the significance of
      some known psychosocial risk factors of smoking in adulthood.
    


Intervention name(s): Brief intervention
Intervention type(s): Behavioral
Intervention description(s): The adolescents were shown a series of photographs of discoloured teeth caused by smoking. Then a mirror was given to the adolescent to let him/her see if similar stains could be seen on his/her teeth. Non-smoking adolescents also received positive feedback for being non-smokers. Duration of a single brief intervention was 2-3 minutes.
Allocation: Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Keywords: Smoking; Adolescence; Brief intervention
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Cancer
Condition: Liver Cancer
MeSH terms: Liver Neoplasms
Study type: Interventional
Phase: Phase 1/Phase 2

Summary: 
      The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional
      therapy using digital subtraction angiography（DSA） for liver cancer.
    

Detailed description: 
      By enrolling patients with liver cancer adapted to enrolled criteria, this study will
      document for the first time the safety and the short and long term efficacy of HepaSphere
      interventional therapy using digital subtraction angiography（DSA） for liver cancer.
    

Intervention name(s): interventional therapy
Intervention type(s): Procedure
Intervention description(s): liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Liver Cancer; HepaSphere
Comparison the Effects of Etomidate and Sevoflurane During Electroconvulsive Therapy
Condition: Anesthesia; ECT
Study type: Interventional
Phase: Phase 4

Summary: 
      The purpose of the study was to investigate the effects of etomidate or sevoflurane used in
      electroconvulsive therapy (ECT) on duration of seizure, hemodynamic response and recovery
      profiles.
    

Detailed description: 
      Twenty-five patients will be a total of 150 ECT treatments in this prospective,
      double-blinded, crossover study. Each patient will receive either 0.2 mg/kg etomidate (Group
      1) or 8% sevoflurane (Group 2) in 100% oxygen at 6 L/min fresh gas flow until loss of
      consciousness for their initial electroconvulsive therapy session. In subsequent sessions,
      patients will receive the alternative sevoflurane concentration and then alternated between
      doses until the sixth session. Muscle paralysis will achieve with 1 mg/kg succinylcholine.
      Motor (EMG) and electroencephalography seizure duration (EEG), heart rate (HR) and mean
      arterial pressure (MAP) values, and recovery times will recorde.
    

Intervention name(s): Etomidate; Sevoflurane
Intervention type(s): Drug; Drug
Intervention description(s): 0.2 mg/kg etomidate; 8% Sevoflurane
Other intervention name(s): Hypnomidate; Sevorane
Intervention MeSH terms: Sevoflurane; Etomidate
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Etomidate; Sevoflurane
Third Year Evaluation on Genistein Efficacy and Safety
Condition: Menopause; Osteopenia
MeSH terms: Bone Diseases, Metabolic
Study type: Observational

Summary: 
      BACKGROUND: Recent evidences showed that the phytoestrogen genistein positively affects bone
      metabolism with no clinically significant adverse effects in a cohort of osteopenic,
      postmenopausal women. However, there is still a knowledge gap regarding the long-term safety
      of genistein on the breast, the uterus, the thyroid gland and its efficacy in postmenopausal
      women.

      OBJECTIVE: To assess the safety profile of genistein on mammary and thyroid glands and
      endometrium and cardiovascular apparatus and its effects on bone metabolism after a 3-year
      therapy with pure, standardized genistein (54 mg/day).
    

Detailed description: 
      DESIGN: The parent study was a randomized, double-blind, placebo-controlled trial involving
      389 osteopenic, postmenopausal women for 24 months. After the 24-month visit, a
      sub-population (138 patients) accepted to continue the intervention until 36 months, thus
      generating a follow-up study.

      SETTING: 3 Italian university medical centers. INTERVENTIONS: Participants received 54 mg of
      genistein, daily, (n=71) or placebo (n=67). Both intervention and placebo contained calcium
      and vitamin D3. All patients also received dietary instruction in an isocaloric fat-reduced
      diet.

      MEASUREMENTS: Mammographic breast density at baseline and after 24 and 36 months was assessed
      by visual classification scale and by digitized quantification. BRCA1 and BRCA2 molecular
      message, sister chromatid exchanges and endometrial thickness were also evaluated at the same
      time points. Measurements of lumbar spine and femoral neck BMD and QUS t-score were assayed
      in our patients. Secondary outcomes were serum levels of B-ALP, IGF-I, sRANKL,
      osteoprotegerin and urinary excretion of CTX, pyridinoline and deoxypyridinoline. Furthermore
      insulin resistance (HOMA-IR), glucose levels, homocysteine and hot flushes were also
      evaluated. In addition for thyroid safety TSH, fT3, fT4, thyroid autoantibodies, and mRNA for
      thyroid and retinoid receptors were evaluated.
    

Intervention name(s): aglycone genistein; placebo
Intervention type(s): Dietary Supplement; Dietary Supplement
Intervention description(s): 2 capsules per day containing 27 mg of aglycone genistein, calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.; 2 capsules per day containing calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
Other intervention name(s): Genivis; Fosteum
Intervention MeSH terms: Genistein
Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Postmenopausal women (age 49-67 yrs)
      
Biospecimen description: 
      whole blood, serum, plasma, urine.
    
Keywords: Genistein; Bone mineral density; digital mammography; safety
The Use of Platelet-Rich Fibrin in Partial Pulpotomy Procedure
Condition: Pulpitis
MeSH terms: Pulpitis
Study type: Interventional

Summary: 
      The aim of this study is to evaluate the clinical and histological pulp responses when MTA
      and a combined of MTA/PRF is used as pulp-capping agents after partial pulpotomy.
    

Detailed description: 
      Partial pulpotomy is generally considered as the treatment of choice for immature permanent
      teeth with reversible injury. Mineral trioxide aggregate (MTA) is a gold standard material as
      pulp capping agent in term of vital pulp therapy. Despite many advantages, MTA has a long
      setting time, little biological inductivity, difficult handling characteristics and high
      cost.

      An essential aspect of tooth tissue engineering is the identification of a suitable scaffold
      to support cell growth and tissue regeneration. Platelet-Rich Fibrin (PRF) is a second
      generation platelet concentrate. It is strictly autologous and helps to release the growth
      factors necessary for the regeneration of dentin pulp complex. Therefore, PRF seems to be a
      suitable scaffold in vital pulp therapy.

      Study sample, 24 intact maxillary or mandibular premolars which will be extracted for
      orthodontic reasons in 12 healthy volunteers. The sample will be chosen from the patients who
      are coming to the Orthodontic department in the Faculty of dentistry - Damascus university.

      This study will be performed as split mouth study. For each selected patient, one premolar
      will be randomly allocated to MTA only and the other to combined MTA/PRF by a toss of coin.
      The main operator will give each patient a numerical code (from 1 to 12) whilst the teeth
      will have an alphabetical coding (e.g. For the patient coded as 1, premolar with MTA will be
      coded as 1-a, the other premolar with MTA/PRF will be coded as 1-b). In all patient
      documents, the teeth will be labeled in the same way so that the clinical examiner and a
      pathologist will be blinded to the capping technique used for each tooth whilst the main
      operator who perform a pulpotomy will know which technique is used for each premolar.

      Postoperative pain and sensitivity to thermal stimuli will be analyzed after the treatment
      between two sides.

      After 8 weeks, the teeth will be extracted and histologically evaluated in terms of
      inflammation, dentin bridge formation and its appearance.
    

Intervention name(s): partial pulpotomy
Intervention type(s): Procedure
Intervention description(s): Removal of a small portion of coronal pulp tissue after exposure, followed by application of a biomaterial directly onto the remaining pulp tissue prior to placement of a permanent restoration.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Partial pulpotomy, platelet rich fibrin